Buprenorphine transdermal patch    (DrugBank: Buprenorphine)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
46悪性関節リウマチ3
70広範脊柱管狭窄症0

46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 4,183 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TCS-14004252
2014-03-042014-02-12A multicenter study for the evaluation of efficacy & safety of buprenorphine transdermal patch (Norspan or Sovenor transdermal patch) in patients with non-malignant pain of moderate to severe intensity due to osteoarthritis, rheumatoid arthritis, lower back pain and joint/muscle pain, when an opioidA multicenter study for the evaluation of efficacy & safety of buprenorphine transdermal patch (Norspan or Sovenor transdermal patch) in patients with non-malignant pain of moderate to severe intensity due to osteoarthritis, rheumatoid arthritis, lower back pain and joint/muscle pain, when an opioid osteoarthritis, rheumatoid arthritis, lower back pain, joint/muscle paincase series:Norspan 5mg patch (1 patch per week), and the dose can be titrated up to maximum 40mg patch in the titration period (maximun 42 days). Patient will then be using the optimum dosage for 11 weeks, and follow-up for another 2 weeks after treatment period, maximum 19 weeks;The Chinese University of Hong KongNULLPending1880Bothcase series:15;I (Phase 1 study)NULL
2NCT02519387
(ClinicalTrials.gov)
July 201315/7/2015Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate IntensityMulticentre Study for Evaluation of the Efficacy and Safety of Buprenorphine Transdermal Patch (SOVENOR®) 5mg and 10mg in Patients With Non-malignant Pain of Moderate Intensity Due to Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain and Joint/Muscle Pain, When an Opioid is Necessary for Obtaining Adequate AnalgesiaOsteoarthritis;Rheumatoid Arthritis;Lower Back Pain;Joint Pain;Muscle PainDrug: Buprenorphine Transdermal PatchMundipharma Pharmaceuticals Sdn. Bhd.NULLCompleted40 YearsN/AAll78Phase 4Malaysia
3NCT01961271
(ClinicalTrials.gov)
June 20137/10/2013Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle PainMulticentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid Is Needed For AnalgesiaOsteoarthritis;Rheumatoid Arthritis;Lower Back Pain;Joint Pain;Muscle PainDrug: Buprenorphine transdermal patchMundipharma Pte Ltd.Mundipharma Korea Ltd;Mundipharma (Hong Kong) Ltd;Mundipharma Distribution GmBH (Philippine Branch)Completed18 Years80 YearsAll114Phase 4Hong Kong;Korea, Republic of;Philippines

70. 広範脊柱管狭窄症 [臨床試験数:91,薬物数:195(DrugBank:54),標的遺伝子数:60,標的パスウェイ数:85
Searched query = "Spinal stenosis", "Extensive spinal canal stenosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 91 trial found